Immatics N.V.
IMTXDrugs in Pipeline
5
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 2 past
No catalysts found.
IMA203
Melanoma, Cutaneous Malignant
GM-CSF
Metastatic Renal Cell Carcinoma
IMA 950
CNS Tumor, Adult
IMA203 Product
Refractory Cancer
IMA970A plus CV8102 and Cyclophosphamide
Hepatocellular Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IMA203 | Phase 3 | Melanoma, Cutaneous Malignant | - | - |
GM-CSF | Phase 3 | Metastatic Renal Cell Carcinoma | - | - |
IMA 950 | Phase 2 | CNS Tumor, Adult | - | - |
IMA203 Product | Phase 2 | Refractory Cancer | - | - |
IMA970A plus CV8102 and Cyclophosphamide | Phase 2 | Hepatocellular Carcinoma | - | - |
Frequently asked questions
What is in Immatics N.V.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Immatics N.V.'s (IMTX) pipeline across Phase 3, Phase 2. Its lead program is IMA203 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Immatics N.V.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Immatics N.V. (IMTX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track IMTX biotech catalysts?→
Add IMTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Immatics N.V.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.